CT-0508 - CARISMA Therap
In-Vivo mRNA CAR-M targeting GPC-3 - Moderna
CT-1119 - CARISMA Therap
CT-0525 - CARISMA Therap
https://www.prnewswire.com/news-releases/carisma-therapeutics-reports-second-quarter-2024-financial-results-and-recent-business-highlights-302217157.html
 
Aug 8, 2024
 
Prev Next